GUANGZHOU, China, March 28, 2025 /PRNewswire/ -- The 137th Canton Fair, set to commence on April 15th in Guangzhou, successfully hosted two promotion conferences on March 18th and 19th in Hong Kong Special Administrative Region and Macao Special Administrative Region, respectively. These events further bridged international trade exchanges and promoted convention and exhibition development in the Guangdong-Hong Kong-Macao Greater Bay Area (Greater Bay Area).
The Deputy Director of China Foreign Trade Centre, Zhang Sihong, conveyed heartfelt gratitude to the Hong Kong and Macao business communities for their longstanding support of the Canton Fair and provided updates on the upcoming 137th session.
The Hong Kong Spring Reception and Canton Fair Promotion Conference was joined by over 260 guests including representatives from Hong Kong Trade and Industry Department, 6 Hong Kong chambers of commerce, 21 foreign chambers of commerce, 17 top multinational corporations, members of the Hong Kong Legislative Council, exhibition industry partners and media.
Dr. Jonathan Choi, Chairman of the Chinese General Chamber of Commerce of Hong Kong stated that the Hong Kong business community has been an active participant and beneficiary of the Canton Fair. He highlighted that, moving forward, Hong Kong businesses can further leverage the Fair as a platform to expand into markets within Belt and Road countries and emerging economies.
The Macao Spring Reception and Canton Fair Promotion Conference on March 19th was attended by 90 guests from Trade Office of the Economic Affairs Department of the Liaison Office of the Central People's Government in Macao SAR, the Economic and Technological Development Bureau (DSEDT), 9 business associations, 17 exhibitors and media.
Xu Lemin, Deputy Secretary of Macao Chamber of Commerce, expressed her hope that more Macao enterprises can showcase the achievements of "manufactured in Macao" and "designed in Macao" to global buyers through the Canton Fair, especially to bring focus to the "Macao and Hengqin" coordinated development advantages and push the regional economic development to new heights.
The Canton Fair, as a prime example of China's Commitment to expand opening-up, provides global buyers with a one-stop trade platform covering a complete range of products and excelling in quality, price, convenience, efficiency and credibility. The 137th Canton Fair will be held from April 15 to May 5, 2025 in Guangzhou. To download the Canton Fair App, please visit https://cief.cantonfair.org.cn/en/app/appintro.html.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
137th Canton Fair Promotes Innovation and Trade in Hong Kong and Macao, Bringing Regional Economy to New Heights
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care
SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.
Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyze whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE® IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.
The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalize treatment approaches for cancer patients. By applying Lunit's AI solutions across NCI's extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimize immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.
"This collaboration with the NCI is a testament to the power and potential of Lunit's AI-driven solutions in advancing the frontier of cancer research," said Brandon Suh, CEO of Lunit. "By applying our technologies across NCI's unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalized care to patients worldwide. We are honored to work with one of the world's leading cancer research institutions to tackle some of the toughest challenges in oncology."
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
